Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Ruben Niesvizky MD

Ruben Niesvizky MD

Director, Myeloma Center, Weill Cornell Medical College-New York Presbyterian Hospital

Dr. Niesvizky is an Associate Professor of Medicine at the Weill Cornell Medical College in New York City where he is the director of the multiple myeloma program. He has written more than 70 articles, editorials, chapters, and abstracts published in journals such as New England Journal of Medicine, Blood, Cancer, Cancer Research and Leukemia & Lymphoma, most recently on topics such as the treatment of myeloma and Waldenstrom’s macroglobulinemia. He has been the director of the clinical core of the Specialized Center of Research (SCOR) of the Leukemia and Lymphoma Society granted in 2000 and is the recipient of various grants and awards from the National Cancer Institute, including a K23 award and 2 translational research grants from the NCI for the development of new drugs. He is the recipient of the 2007 Investigator Award of the Michael Wolk Heart Foundation and was finalist at the Man or the Year 2011 event of the Leukemia and Lymphoma Society. A frequent lecturer, Dr. Niesvizky regularly presents at annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, of which he is also a member. He is an active participant in clinical trials of promising new drugs and medical procedures for the treatment of myeloma, lymphoma, and related hematologic disorders.